Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | APC wild-type CTNNB1 wild-type |
Therapy | Vantictumab |
Indication/Tumor Type | colon cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC wild-type CTNNB1 wild-type | colon cancer | predicted - sensitive | Vantictumab | Preclinical - Pdx | Actionable | In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465). | 22753465 |
PubMed Id | Reference Title | Details |
---|---|---|
(22753465) | Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. | Full reference... |